Biotechnology company and global drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP)today announced the granting of four of its pending
patent applications via its wholly-owned subsidiary Poviva Corp. According to
the update, the new patents cover delivery of cannabinoids such as THC and CBD,
NSAIDs such as ibuprofen, nicotine, and vitamins. With issuance of these four
patents, Lexaria’s total patents granted has increased to 15, with eight in the
US and seven in Australia, and the company has roughly 60 patent applications
pending throughout the world. Lexaria is one of the most patent-rich firms in
the Western World for effective blood plasma delivery of cannabis-related
compounds in the cannabis or hemp industries with 15 patents already granted
for the delivery of cannabinoids.
To view the full press release, visit http://ibn.fm/Gpdjg
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the company’s
website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
